AU · rank #3 · 2026-07-20
NUTX
NASDAQ · $1.12B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.966 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.58 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.194 |
| Analyst upside Consensus target $246.40 | +51.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +42.69% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +50.6% |
| 52w high | $204.00 |
| Market cap (USD) | $1.12B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health Inc. is a physician-led, technology-enabled healthcare services company that operates approximately 27 micro-hospitals across 12 states alongside a population health management division.
Rationale
The quant signal's 51% analyst upside and 100% revision agreement are validated by stellar fundamental momentum, including Q1 2026 earnings that more than doubled and strong operating cash flow of $75.5 million.
Material risks
- 1Heavy reliance on the No Surprises Act's Independent Dispute Resolution arbitration process to resolve reimbursement disputes leaves revenues and EBITDA highly vulnerable to regulatory changes and arbitration timing.
- 2Elevated capital expenditure and execution risks stemming from management's strategic shift to internally funding new micro-hospital construction prior to executing sale-leaseback transactions.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.